



# CSIR

## New Millennium Indian Technology Leadership Initiative (CSIR-NMITLI)

A Unique Public-Private Partnership Programme for Achieving Breakthrough Innovation

Challenge Your  
Innovation Potential  
and Deliver  
Breakthrough  
Technological  
Interventions to Create  
Corona Mukht Bharat

CSIR Call to Industry and  
Startups to submit Challenge  
Driven R&D Proposals

Opportunity to  
Work for Grand  
Challenge along  
with the Very  
Best of the Minds

### CSIR approves first project in lieu of above call under CSIR-NMITLI on Novel Therapy for Management of COVID-19

Heat killed Mycobacterium w (Mw) is an approved immunomodulatory in India since 1998. It is an outcome of extensive research carried out by Indian scientists spanning more than two decades. It induces a pure potent Th1 response following its administration through the intradermal route.

Council of Scientific and Industrial Research (CSIR) through its NMITLI program had supported Cadila Pharmaceuticals Ltd., Ahmedabad for developing the drug (Mw) for saving lives of critically ill patients suffering from gram-negative sepsis.

Looking at similarities between clinical characteristics of patients suffering from COVID-19 and gram-negative sepsis, CSIR in partnership with Cadila Pharmaceuticals is now initiating a landmark clinical trial to evaluate this drug (Mw) in critically ill COVID-19 patients to reduce the mortality. It is found to be extremely safe in patients and no systemic side effects are associated with its use. It can be used concurrently with any other therapies required in the management of such critically ill patients without any restriction.

The trial will be a randomized, blinded, two arms, active comparator-controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in providing prophylaxis against COVID-19 infection. DCGI has approved the trial and it will start soon at multiple hospitals where COVID-19 infected patients are being treated.

\*\*\*